SSI Strategy Whitepaper

Integrated Medical Leadership: Moving Beyond the Fractional CMO Model

Written by:
Steve Zelenkofske et al.

SSI Strategy

The biotech industry faces a fundamental challenge in medical leadership that extends beyond resource constraints. As drug development becomes increasingly complex, the traditional expectation that a single Chief Medical Officer (CMO) can effectively oversee all medical and clinical aspects of an organization has become unrealistic. This structural challenge manifests most visibly in the growing trend of fractional CMO appointments, where companies engage medical leadership on a part-time basis.

In boardrooms across the biotech landscape, this fractional approach has emerged as a seemingly elegant solution to immediate resource constraints - early-stage companies need top-tier medical leadership but often lack the resources for a full-time executive. However, this apparent solution not only fails to address the underlying challenge but potentially amplifies it: the scope and complexity of modern medical leadership cannot reasonably reside in a single individual, regardless of their time commitment. The role of a CMO is not just a job; it's a juggling act of epic proportions. From translating complex science for investors to addressing regulatory requirements, from ensuring patient safety to shaping clinical strategy, the CMO keeps multiple critical elements in constant motion. This complexity presents challenges in both full-time and part-time arrangements. The fractional CMO model, while addressing immediate budgetary concerns, further introduces a host of unforeseen challenges. It fragments a role that, by its very nature, demands continuity, deep integration, and unwavering commitment.

The effectiveness of any medical leadership model depends on two critical operational foundations: robust program management and clear communication pathways. Without these operational pillars, even the most skilled medical leadership will struggle to execute effectively.

This paper examines the multifaceted world of the CMO, exploring both the inherent limitations of concentrating all medical leadership in a single individual and the additional challenges that arise in the fractional approach, before proposing a more holistic model of medical leadership. Our goal is to challenge the status quo and offer a framework that aligns with the complex, high-stakes nature of biotech innovation.

The CMO's Sphere of Influence

While traditional models attempt to concentrate all CMO functions on a single individual, understanding the full scope helps illustrate why this approach has become increasingly challenging. The role demands a diverse set of skills and capabilities that collectively shape medical leadership in biotech organizations. While no person typically possesses mastery across all these domains, understanding this comprehensive scope is crucial for building effective medical leadership:

» **Leadership and Organizational Excellence**

The CMO builds and leads high-performing teams while fostering a strong cultural foundation. This includes developing effective governance structures, managing resources, and establishing collaborative relationships across functions and divisions. Success in this domain requires balancing team workload while maintaining operational efficiency through appropriate delegation and meetings management.

» **Strategic Communication and External Engagement**

At its core, this role demands exceptional communication abilities across multiple contexts. The CMO crafts and delivers scientific and clinical narratives tailored to diverse audiences, from investors to board members. They must develop compelling medical narratives that effectively communicate value milestones while maintaining scientific credibility. This includes managing investor relations with appropriate gravitas and serving as the lead medical voice for both internal and external stakeholders.



» **Executive Leadership and Business Acumen**

The CMO contributes crucial medical perspective to executive decision-making, particularly in pipeline and program prioritization within financial constraints. They manage portfolio decisions and budget allocation while participating in strategic planning and risk management. Critical to this function is the ability to partner effectively with program management to track and achieve key milestones.

» **Operational and Development Expertise**

Successful medical leadership requires oversight of functional teams across Clinical Development, Clinical Operations, Medical Affairs, Translational Medicine, HEOR, and Pharmacovigilance. The CMO manages vendor relationships and execution strategies while leading global regulatory interactions. This demands a comprehensive understanding of the drug development lifecycle from candidate selection through commercialization.

» **Cross-functional Integration**

The role necessitates building effective interfaces between R&D, Regulatory, Commercial, and Safety functions. The CMO optimizes resource utilization based on company stage while maintaining strong partnerships with Contract Research Organizations (CROs) and other external partners. This integration ensures cohesive execution across all aspects of drug development.

» **Medical Leadership and Patient Advocacy**

Above all, the CMO serves as the guardian of patient interests and organizational integrity. They provide medical expertise for critical decision-making while engaging with Key Opinion Leaders and patient advocacy groups. This responsibility demands maintaining scientific and medical credibility in all initiatives.

A crucial attribute that underpins all these responsibilities is self-awareness - recognizing that no single individual excels in all these areas. Successful CMOs understand their strengths and limitations, knowing when and how to leverage additional expertise through their team, consultants, or external partners.

This comprehensive scope illustrates a fundamental challenge in modern biotech: attempting to concentrate these diverse responsibilities in a single individual - whether full-time or fractional - creates inherent limitations and risks. The fractional model merely amplifies these existing challenges.

The Fractional CMO Model: A Closer Examination

While the challenges discussed below are particularly acute in part-time arrangements, many reflect fundamental issues inherent to concentrating all medical leadership responsibilities in a single individual, regardless of time commitment. When implementing the fractional CMO model, a series of unforeseen challenges are emerging, revealing the complex interplay between medical leadership and successful drug development:

» **Time Allocation Mismatch**

The role of a CMO typically demands far more than a standard 40-hour work week. When companies opt for a fractional CMO, they often underestimate the time required for comprehensive oversight. A part-time arrangement doesn't simply equate to half of a full-time CMO's contribution. The reality is that critical tasks and decisions may not align neatly with predetermined schedules, potentially leaving the company vulnerable during off-hours.

» **Prioritization Dilemmas**

With limited hours at their disposal, fractional CMOs face the daunting task of prioritizing a wide array of responsibilities. This can lead to situations where certain critical areas receive insufficient attention. The challenge lies in determining which aspects of the role can be adequately addressed in a part-time capacity and which require more consistent engagement.

» **Strategic Continuity Gaps**

The biotech landscape is dynamic, with new data, competitive moves, and regulatory changes occurring frequently. Depending on the arrangement and the CMO's other responsibilities, a part-time CMO may not be available at crucial moments when quick, informed decisions are necessary. This can result in missed opportunities or delayed responses to emerging issues, potentially impacting the overall trajectory of drug development programs.

» **Ethical and Safety Concerns**

Patient safety and ethical decision-making are paramount in drug development. The fractional model raises questions about how to ensure continuous oversight of safety-related issues, although this responsibility lies with the leadership team. There's a risk that critical safety signals or ethical dilemmas might arise during periods when the CMO is not accessible, potentially compromising the company's ability to respond promptly and appropriately.

» **Loss of Synergistic Effects**

The CMO role is multifaceted, involving the simultaneous management of various interconnected responsibilities. By fragmenting this role, companies may lose the synergistic benefits that come from having a single, fully-engaged individual overseeing and connecting different aspects of medical strategy and operations. This holistic perspective is necessary for navigating the complex interplay of scientific, regulatory, and commercial considerations in drug development.

» **Misalignment of Expectations**

Many companies, especially those new to drug development, may not fully grasp the breadth and depth of a CMO's responsibilities. This can lead to unrealistic expectations of what can be accomplished in a part-time capacity. There's a risk of overlooking or undervaluing certain critical functions, potentially leaving gaps in the company's medical leadership.

» **Long-term Strategic Planning Challenges**

Effective drug development requires long-term strategic planning. A fractional CMO, with limited hours and potentially divided focus, may struggle to engage deeply in comprehensive, forward-looking strategizing. This could impact the company's ability to anticipate and prepare for future challenges and opportunities in the ever-evolving biotech landscape.

These are some of the challenges a fractional CMO encounters and highlight the complex nature of the CMO role and the potential pitfalls of this model. While the approach may seem to address immediate resource constraints, it raises significant questions about its long-term effectiveness in supporting a company's drug development goals and overall success.

Reframing Medical Leadership

To address both the inherent limitations of the traditional CMO role and the limitations of the traditional fractional CMO model, we suggest a paradigm shift: moving from the concept of a single leader – whether full-time or part-time - to that of a fractional function. This approach aims to maintain operational efficiency while ensuring comprehensive coverage of all critical CMO responsibilities. Here's how this model works:

1. **Assessment and Roadmap:**
   Before engaging any medical leadership, companies should conduct a thorough evaluation of their specific needs. This involves mapping out all necessary CMO functions and how they align with the company's current stage and future goals. This assessment creates a clear roadmap of medical leadership requirements, allowing for more targeted and efficient resource allocation.

2. **Function-Based Allocation:**
   Instead of hiring a single part-time CMO, companies distribute CMO responsibilities across a team of specialists. Each team member focuses on specific functions where they have deep expertise. For instance, one specialist might handle regulatory strategy, another clinical development, and a third safety and pharmacovigilance. By having dedicated specialists for each function, this model ensures continuous coverage of critical areas. Unlike a single part-time CMO, there's always someone available to address urgent matters in their specific domain.

3. **Flexible Scaling and Cost-Effective Expertise:**
   This model allows companies to scale different functions up or down based on current needs. During critical phases like trial design or regulatory submissions, relevant functions can be expanded temporarily without committing to full-time, long-term expenses. This approach allows companies to access top-tier expertise in each functional area without the cost of a full-time, highly experienced CMO. It's particularly beneficial for early-stage companies that need specialized knowledge but can't justify the expense of a full executive team.

4. **Maintaining Strategic Oversight:**
   While functions are distributed, it's essential to maintain cohesive strategic direction. This model includes a senior medical advisor and partner to the CEO and leadership suite or to the board, who provides high-level oversight, ensuring all specialized functions align with the company's overall strategy and goals, while maintaining the bandwidth to serve as a trusted leadership advisor.

5. **Leveraging External Expertise:**
   The fractional function model often involves partnering with specialized consultancies or service providers. These external partners can fill specific functional gaps as needed, providing access to a broader range of expertise than a single CMO could offer.

6. **Adaptability to Company Growth:**
   As the company evolves, this model allows for easy transition. Functions can be brought in-house as full-time roles when the needs and resources align, without disrupting the overall medical leadership structure, while identifying evolving needs and gaps as the company grows.

When Fractional Leadership Works

While this paper advocates for a more comprehensive approach to medical leadership, there are specific scenarios where a traditional fractional CMO model remains appropriate:

- Companies focused on generic drug development, where the regulatory pathway is well-defined and requires less intensive medical oversight
- Organizations developing drug delivery technologies or platforms, particularly those with established safety profiles
- Businesses creating adjunct products for B2B applications, where clinical development complexity is reduced
- Companies with products in maintenance phases requiring periodic rather than continuous medical input

In these cases, the reduced complexity or established nature of the development pathway aligns well with fractional medical leadership. However, even in these scenarios, companies should regularly assess whether their medical leadership model continues to meet their evolving needs.

Medical Leadership – the Next Generation

The evolution of drug development has exposed the limitations of traditional medical leadership models. By adopting this 'Seed-to-Scale' Medical Office approach to medical leadership, companies can ensure they have access to the right expertise at the right time, without compromising on strategic oversight or operational efficiency. This model allows for greater flexibility, scalability, and ultimately, may lead to more successful drug development programs.

Rather than attempting to find the perfect individual or deciding between full-time and fractional arrangements, this model addresses many of the limitations of the traditional fractional CMO approach. It provides comprehensive coverage of all CMO responsibilities while offering the flexibility and cost-effectiveness that resource-constrained biotech companies need.

The success of this model depends heavily on strong operational foundations. Robust program management ensures that distributed medical leadership functions remain coordinated and effective.

This shift requires a change in mindset from both companies and medical leaders. It demands clear communication, strong coordination, and a commitment to integration. However, when implemented effectively, it has the potential to provide more robust and adaptable medical leadership, ultimately supporting better drug development outcomes.

Conclusion

As the biotech industry continues to push the boundaries of science and medicine, its approach to leadership must evolve accordingly. The traditional concept of a Chief Medical Officer as a single, indivisible role is no longer sufficient for the complex, fast-paced world of modern drug development.

The challenges observed with fractional CMO models have helped highlight a broader truth: the traditional approach to medical leadership requires fundamental restructuring. Seed-to-Scale Medical Office model offers a revolutionary approach, disaggregating the CMO role into its core components. This allows companies to access specialized expertise across all critical areas of medical leadership, creating an effective combination of functions to drive success.

Implementing this model requires a complete reimagining of medical leadership in biotech. It demands moving beyond the ingrained notion of the CMO as an individual and instead envisioning leadership as a set of essential functions that can be flexibly combined to meet specific needs. This shift offers significant benefits: enhanced expertise in every area, greater adaptability to changing demands, and more efficient use of resources.

By embracing this functional view, companies can better position themselves to take on the challenges of drug development, accelerate innovation, and ultimately bring life-changing therapies to patients more effectively. The future of medical leadership in biotech lies not in finding the perfect individual, but in creating the perfect combination of functions to drive success.

About the authors

Steve Zelenkofske

Member of SSI Strategy Executive Advisory Network with over 20 years of experience in biopharmaceutical, medical device, and gene therapy industries. He has a strong background in cardiovascular, neurology, and immunology, and has held several leadership roles as Chief Medical Officer, contributing to significant advancements in these fields.

Benit Maru

SVP, Medical at SSI Strategy. An academic physician and health economist with extensive experience in neurology, neuroimmunology, and health economics. Benit has significant experience as a Chief Medical Officer and has contributed to numerous clinical research and development projects.

Jen Seda

SVP, Medical at SSI Strategy. With over 20 years of expertise in rare disease, device, and innovative therapeutics, she has served as interim CMO and led medical affairs teams, driving successful clinical trials and medical affairs activities.

Minna Montgomery

Vice President at SSI Strategy with deep expertise in cell and gene therapy. Minna has extensive experience in clinical development, market access, and digital strategy, supporting the successful global commercialization of several biologics.

Carrie Brownstein

SVP, Medical at SSI Strategy. An accomplished drug developer with over 15 years of expertise in hematology, oncology, and rare diseases. Carrie successfully built high-performing teams and led the development of innovative therapies targeting significant unmet medical needs.

Laurie Smaldone Alsup

SVP Regulatory Services at SSI Strategy. With over 25 years of experience in drug development and global regulatory affairs, Laurie has successfully led global product approvals across major therapeutic areas.

Kim Kushner

Chief Business Officer at SSI Strategy with over 12 years of experience in healthcare. Kim specializes in strategic planning, program leadership, and corporate governance. She has worked across all medical office functions as well as on corporate enablement directly with CEOs and Boards of Directors.

Trevor Mill

SVP, Regulatory at SSI Strategy. With over 30 years of experience in pharma, biotech, and startups, Trevor has advanced novel compounds and led R&D, achieving key development milestones. He has extensive experience in global regulatory filings and approvals.

Debra Aub Webster

VP, Regulatory at SSI Strategy. With over 25 years of experience in nonclinical and regulatory affairs, Debra has held significant roles in regulatory strategy and consulting. She has contributed to successful regulatory submissions and approvals across various therapeutic areas.

More Than a Service Provider

We are your dedicated partner in turning groundbreaking ideas into tangible solutions that make a difference. Combining our therapeutic expertise with strategic problem-solving, we help you overcome obstacles and reach every milestone on your journey.

Let's talk!

SSI Strategy

www.ssistrategy.com